Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

PURPOSE: Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Gandhi, Leena, Camidge, D. Ross, Ribeiro de Oliveira, Moacyr, Bonomi, Philip, Gandara, David, Khaira, Divis, Hann, Christine L., McKeegan, Evelyn M., Litvinovich, Elizabeth, Hemken, Philip M., Dive, Caroline, Enschede, Sari H., Nolan, Cathy, Chiu, Yi-Lin, Busman, Todd, Xiong, Hao, Krivoshik, Andrew P., Humerickhouse, Rod, Shapiro, Geoffrey I., Rudin, Charles M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4668282/
https://ncbi.nlm.nih.gov/pubmed/21282543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6208
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars